|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Current status of intravenous tissue plasminogen activator dosage for acute ischaemic stroke:an updated systematic review显示文摘The optimal dose of recombinant tissue plasminogen activator(rtPA)for acute ischaemic stroke(AIS)remains controversial,especially in Asian countries.We aimed to update the evidence regarding the use of low-dose versus standard-dose rtPA.We performed a systematic literature search across MEDLINE,Embase,Cochrane Central Register of Controlled Trials(CENTRAL),PsycINFO and Cumulative Index to Nursing and Allied Health Literature(CINAHL)from inception to 22 August 2016 to identify all related studies.The outcomes were death or disability(defined by modified Rankin Scale 2-6),death,and symptomatic intracerebral haemorrhage(sICH).Where possible,data were pooled for meta-analysis with ORs and corresponding 95% CIs by means of random-effects or fixed-effects meta-analysis.We included 26 observational studies and 1 randomised controlled trial with a total of 23210 patients.Variable doses of rtPA were used for thrombolysis of AIS in Asia.Meta-analysis shows that low-dose rtPA was not associated with increased risk of death or disability(OR 1.13,95% CI 0.95 to 1.33),or death(OR 0.86,95% CI 0.74 to 1.01),or decreased risk of sICH(OR 1.06,95% CI 0.65 to 1.72).The results remained consistent when sensitivity analyses were performed including only low-dose and standard-dose rtPA or only Asian studies.Our review shows small difference between the outcomes or the risk profile in the studies using low-dose and/or standard-dose rtPA for AIS.Low-dose rtPA was not associated with lower risk of death or disability,death alone,or sICH. | Xia Wang Shoujiang You Shoichiro Sato Jie Yang Cheryl Carcel Danni Zheng Sohei Yoshimura Craig S Anderson Else Charlotte Sandset Thompson Robinson John Chalmers Vijay K Sharma | 2018 | Stroke & Vascular Neurology2018，3，1： | 10 |
| 2 | Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial显示文摘 | Craig S Anderson Yining Huang Ji Guang Wang Hisatomi Arima Bruce Neal Bin Peng Emma Heeley Christian Skulina Mark W Parsons Jong Sung Kim Qing Ling Tao Yue Chun Li Jian Dong Jiang Li Wen Tai Jin Li Zhang En Xu Yan Cheng Stephane Heritier Lewis B Morgenste | 2008 | Lancet Neurology2008，，5： | 4 |
| 3 | Effectiveness of intravenous r- tPA versus UK for acute ischaemic stroke: a nationwide prospective Chinese registry study显示文摘Background Intravenous recombinant tissue plasminogen activator(r-tPA)and urokinase(UK)are both recommended for the treatment of acute ischaemic stroke(AIS)in China,but with few comparative outcome data being available.We aimed to compare the outcomes of these two thrombolytic agents for the treatment of patients within 4.5 hours of onset of AIS in routine clinical practice in China.Methods A pre-planned,prospective,nationwide,multicentre,real-world registry of consecutive patients with AIS(age≥18 years)who received r-tPA or UK within 4.5 hours of symptom onset according to local decision-making and guideline recommendations during 2017-2019.The primary effectiveness outcome was the proportion of patients with an excellent functional outcome(defined by modified Rankin scale scores 0 to 1)at 90 days.The key safety endpoint was symptomatic intracranial haemorrhage according to standard definitions.Multivariable logistic regression was used for comparative analysis,with adjustment according to propensity scores to ensure balance in baseline characteristics.Results Overall,4130 patients with AIS were registered but 320 had incomplete or missing data,leaving 3810 with available data for analysis of whom 2666 received r-tPA(median dose 0.88(IQR 0.78-0.90)mg/kg)and 1144 received UK(1.71(1.43-2.00)×104 international unit per kilogram).There were several significant intergroup differences in patient characteristics:r-tPA patients were more educated,had less history of stroke,lower systolic blood pressure,greater neurological impairment and shorter treatment times from symptom onset than UK patients.However,in adjusted analysis,the frequency of excellent outcome(OR 1.18,95%CI 1.00 to 1.40,p=0.052)and symptomatic intracranial haemorrhage(OR 0.70,95%CI 0.33 to 1.47,p=0.344)were similar between groups.Conclusions UK may be as effective and carry a similar safety profile as r-tPA in treating mild to moderate AIS within guidelines in China.Registration http://www.clinicaltrials.gov.unique identifier:NCT02854592. | Xinhong Wang Xiaoqiu Li Yuming Xu Runhui Li Qingcheng Yang Yong Zhao Fengyun Wang Baoying Sheng Runqing Wang Shaoyuan Chen Lihua Wang Liying Shen Xiaowen Hou Yu Cui Duolao Wang Bin Peng Craig S Anderson Huisheng Chen On behalf of INTRECIS Investigators | 2021 | Stroke & Vascular Neurology2021，6，4： | 2 |
| 4 | Epidemiological investigation of infectious hematopoietic necrosis virus in salt water net-pen reared Atlantic salmon in British Columbia, Canada显示文摘 | Sophie St-Hilaire Carl S Ribble Craig Stephen Eric Anderson Gael Kurath Michael L Kent | 2002 | Aquaculture2002，，1： | 2 |
| 5 | Characteristics,management and response to alteplase in China versus non-China participants of the ENCHANTED trial显示文摘Background The characteristics of patients with acute ischaemic stroke(AIS)and their management vary across regions,which may influence outcomes.We examined for differential patterns of outcome between China and non-China participants of the ENhanced Control of Hypertension And Thrombolysis strokE stuDy(ENCHANTED),which tested different alteplase doses in AIS.Methods ENCHANTED was an international,multicentre,open,blinded-endpoint trial of the effects of low-dose(0.6 mg/kg)versus standard-dose(0.9 mg/kg)intravenous alteplase on 90-day disability outcomes and symptomatic intracerebral haemorrhage(sICH)in 3310 patients with AIS.Results Participants(n=1419,48%)in China were younger,and more often male,hypertensive and with prior stroke and coronary artery disease,but less likely to have atrial fibrillation and use antihypertensive,antithrombotic and lipid-lowering agents,compared with non-China patients with AIS.Although China participants had more AIS due to large artery occlusion,were treated later and had differing ancillary management,there was no significant difference in 90-day modified Rankin scale scores 2–6(55.6% vs 47.8%;OR,adjusted for baseline and management factors 0.87(95%CI 0.71 to 1.07;p=0.20))and risk of sICH(Safe Implementation of Thrombolysis in Stroke-Monitoring Study criteria:1.4% vs 1.8%;p=0.12)compared with non-China participants.There was no heterogeneity in the treatment effects of low-dose versus standard-dose alteplase between China and non-China participants.Conclusion Patients with AIS recruited to the ENCHANTED trial in China had similar outcomes in response to thrombolysis treatment despite significantly differing demographic,clinical and management factors to patients with AIS in other regions. | Lily Song Xia Wang Thompson Robinson Richard I Lindley Hisatomi Arima Pablo M Lavados Xiaoying Chen John Chalmers Craig S Anderson | 2017 | Stroke & Vascular Neurology2017，2，2： | 1 |
| 6 | Smoking influences outcome in patients who had thrombolysed ischaemic stroke:the ENCHANTED study显示文摘Background and purpose As studies vary in defining the prognostic significance of smoking in acute ischaemic stroke(AIS),we aimed to determine the relation of smoking and key outcomes in patient participants who had thrombolysed AIS of the international quasi-factorial randomised Enhanced Control of Hypertension and Thrombolysis Stroke Study(ENCHANTED).Methods Post-hoc analyses of ENCHANTED,an international quasi-factorial randomised evaluation of intravenous alteplase-dose comparison and levels of blood pressure control in patients who had thrombolysed AIS.Multivariable logistic regression models with inverse probability of treatment weighting(IPTW)propensity scores were used to determine associations of self-reported smoking status and clinical outcomes,according to 90-day modified Rankin Scale(mRS)scores and symptomatic intracerebral haemorrhage(sICH).Results Of 4540 patients who had an AIS,there were 1008(22.2%)current smokers who were younger and predominantly male,with more comorbidities of hypertension,coronary artery disease,atrial fibrillation and diabetes mellitus,and greater baseline neurological impairment,compared with non-smokers.In univariate analysis,current smokers had a higher likelihood of a favourable shift in mRS scores(OR 0.88,95%CI 0.77 to 0.99;p=0.038)but this association reversed in a fully adjusted model with IPTW(adjusted OR 1.15,95%CI 1.04 to 1.28;p=0.009).A similar trend was also apparent for dichotomised poor outcome(mRS scores 2–6:OR 1.18,95%CI 1.05 to 1.33;p=0.007),but not with the risk of sICH across standard criteria.Conclusion Smoking predicts poor functional recovery in patients who had thrombolysed AIS.Trial registration number NCT01422616. | Lingli Sun Lili Song Jie Yang Richard I Lindley Thompson Robinson Pablo M Lavados Candice Delcourt Hisatomi Arima Bruce Ovbiagele John Chalmers Craig S Anderson Xia Wang | 2021 | Stroke & Vascular Neurology2021，6，3： | 1 |
| 7 | 5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial显示文摘 | Michael J Mack Martin B Leon Craig R Smith D Craig Miller Jeffrey W Moses E Murat Tuzcu John G Webb Pamela S Douglas William N Anderson Eugene H Blackstone Susheel K Kodali Raj R Makkar Gregory P Fontana Samir Kapadia Joseph Bavaria Rebecca T Hahn Vinod H | 2015 | The Lancet . 2015 (9986)2015，，： | 1 |
| 8 | Intensive blood pressure reduction in acute cerebral haemorrhage trial (INTERACT): a randomised pilot trial显示文摘 | Craig S Anderson Yining Huang Ji Guang Wang Hisatomi Arima Bruce Neal Bin Peng Emma Heeley Christian Skulina Mark W Parsons Jong Sung Kim Qing Ling Tao Yue Chun Li Jian Dong Jiang Li Wen Tai Jin Li Zhang En Xu Yan Cheng Stephane Heritier Lewis B Morgenste | 2008 | Lancet Neurology2008，，5： | 1 |
| 9 | Suboptimal a wareness and control of hypertension increases the risk of subarachnoid hemorrhage in the community: results from the ACROSS 显示文摘 | Ivy Shiue Graeme J Hankey Hisatomi Arima Craig S Anderson | 2011 | Neurological research2011，33，10： | 1 |
| 10 | Precision management of brain oedema after acute ischaemic stroke显示文摘Dear Editor,Stroke is a leading cause of death and disability in the world,with acute ischaemic stroke accounting for∼70%of all cases.1 Some degree of brain oedema occurs in all cases of acute ischaemic stroke and,when severe,has major consequences on survivalfree of disability.Pathophysiological studies indicate an evolution of cytotoxic oedema,ionic oedema,and vasogenic oedema,2 which implies brain oedema is a dynamic process and explains the various terminology used,such as large hemispheric infarction,symptomatic infarct swelling,space-occupying infarction,or malignant middle cerebral artery(MCA)infarction.Heterogeneity in manifestations and sequelae necessitates a new,precision medicine approach to individualizing prevention and treatment of brain oedema after stroke. | Simiao Wu Craig S Anderson | 2022 | Precision Clinical Medicine2022，5，3： | 0 |
| 11 | No benefit of flat head positioning in early moderate-severe acute ischaemic stroke: a HeadPoST study subgroup analysis显示文摘background Although the Head Positioning in acute Stroke Trial(HeadPoST)showed no effect of the flat head position(FP;vs sitting up head position(SUP))on functional outcome,we hypothesised that it could still offer benefits if commenced early in those with acute ischaemic stroke(AIS)of at least moderate severity.Methods Subgroup analysis of HeadPoST in participants with National Institutes of Health Stroke Scale(NIHSS)scores≥7,≥10 and≥14,randomised to FP or SUP<4.5 hours of AIS onset on functional outcomes defined by a shift in scores on the modified Rankin scale(mRS)and death/disability(mRS scores 3-6),and any cardiovascular serious adverse event.Logistic regression analyses were undertaken adjusted for study design and baseline risk factors.results There was no significant differential treatment effect in patient subgroups defined by increasing baseline NIHSS scores:adjusted OR and 95%CI for ordinal shift and binary(3-6)mRS scores:for NIHSS≥7(n=867)0.92(0.67 to 1.25)and 0.74(0.52 to 1.04);NIHSS≥10(n=606)0.80(0.58 to 1.10)and 0.77(0.49 to 1.19);NIHSS≥14(n=378)0.82(0.54 to 1.24)and 1.22(0.69 to 2.14).Conclusions Early FP had no significant effect in patients with moderate-severe AIS. | Alejandro M Brunser Menglu Ouyang Hisatomi Arima Pablo M Lavados Thompson Robinson Paula Munoz-Venturelli Veronica V Olavarria Laurent Billot Marre L Hackett Lili Song Sandy Middleton Octavio Pontes-Neto Tsong-Hai Lee Caroline Watkins Craig S Anderson | 2020 | Stroke & Vascular Neurology2020，5，4： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员